Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries announced that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic version of semaglutide injection. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for chronic weight management in adults as an adjunct to a reduced calorie diet and increased physical activity. Sun Pharma will launch generic semaglutide injection under the brand name, Noveltreat, after the expiry of semaglutide patent in India. The product has received approval from the DCGI following a review of a Phase III clinical trial conducted in India. Noveltreat will be available in five dose strengths - 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL, with a maintenance dose of 2.4 mg once weekly. The product is administered via an easy-to-use prefilled pen, designed to support convenient and accurate dosing. 'Obesity and diabetes have emerged as two of the most pressing health challenges confronting India and GLP-1 based therapies can play a meaningful role in addressing this growing burden. Noveltreat meets global quality standards and is supported by robust Indian clinical evidence on efficacy and safety for weight management. As India's largest pharmaceutical company with leadership in cardiometabolic therapies, we are committed to improving access to generic semaglutide across the country after the patent expiry', said Kirti Ganorkar, Managing Director, Sun Pharma. 'GLP-1 receptor agonists like semaglutide are an important scientific advancement for overall metabolic health, not just weight. These treatments should be combined with appropriate lifestyle measures such as diet and physical activity. They should be taken under close medical supervision. We are seeing growing patient interest in this therapy, and improved accessibility will help address unmet needs', said Dr. Unnikrishnan A G, Chief Endocrinologist and CEO, Chellaram Diabetes Institute. In December 2025, Sun Pharma received DCGI approval for manufacturing and marketing semaglutide injection for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise. It will be launched under the brand name Sematrinity, after the expiry of semaglutide patent in India.Powered by Capital Market - Live

Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 January 2026.Powered by Capital Market - Live

Sun Pharmaceutical Industries has fixed 05 February 2026 as record date for payment of interim dividend, if declared. Powered by Capital Market - Live

Zen Technologies Ltd, Bharti Hexacom Ltd, HDFC Asset Management Company Ltd, CG Power & Industrial Solutions Ltd are among the other stocks to see a surge in volumes on BSE today, 16 January 2026.Sun Pharmaceutical Industries Ltd saw volume of 10.12 lakh shares by 10:46 IST on BSE, a 9.33 fold spurt over two-week average daily volume of 1.08 lakh shares. The stock dropped 1.03% to Rs.1,683.00. Volumes stood at 89093 shares in the last session.Zen Technologies Ltd clocked volume of 2.79 lakh shares by 10:46 IST on BSE, a 8.53 times surge over two-week average daily volume of 32722 shares. The stock gained 8.09% to Rs.1,327.85. Volumes stood at 34570 shares in the last session.Bharti Hexacom Ltd recorded volume of 3.06 lakh shares by 10:46 IST on BSE, a 5.73 times surge over two-week average daily volume of 53492 shares. The stock lost 1.93% to Rs.1,607.60. Volumes stood at 2.59 lakh shares in the last session.HDFC Asset Management Company Ltd saw volume of 2.53 lakh shares by 10:46 IST on BSE, a 4.58 fold spurt over two-week average daily volume of 55278 shares. The stock increased 3.97% to Rs.2,656.10. Volumes stood at 1.94 lakh shares in the last session.CG Power & Industrial Solutions Ltd witnessed volume of 10.8 lakh shares by 10:46 IST on BSE, a 4.58 times surge over two-week average daily volume of 2.36 lakh shares. The stock dropped 0.30% to Rs.575.20. Volumes stood at 1.29 lakh shares in the last session.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1761, up 0.05% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 26083.25. The Sensex is at 84758.67, down 0.36%. Sun Pharmaceutical Industries Ltd has dropped around 1.96% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has dropped around 2.31% in last one month and is currently quoting at 23126.85, up 0.16% on the day. The volume in the stock stood at 17.39 lakh shares today, compared to the daily average of 18.59 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1769.3, up 0.23% on the day. Sun Pharmaceutical Industries Ltd is down 4.18% in last one year as compared to a 10.11% gain in NIFTY and a 0.66% gain in the Nifty Pharma index.The PE of the stock is 90.36 based on TTM earnings ending September 25.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1712.2, down 0.29% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.17% on the day, quoting at 25897.6. The Sensex is at 84563.41, down 0.16%.Sun Pharmaceutical Industries Ltd has eased around 5.27% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has eased around 2.07% in last one month and is currently quoting at 22578.3, down 0.72% on the day. The volume in the stock stood at 9.85 lakh shares today, compared to the daily average of 20.24 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1714.9, up 0.02% on the day. Sun Pharmaceutical Industries Ltd tumbled 9.23% in last one year as compared to a 9.53% rally in NIFTY and a 4.26% fall in the Nifty Pharma index.The PE of the stock is 88.17 based on TTM earnings ending September 25.Powered by Capital Market - Live

The American drug regulator had inspected the company's facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). 'We continue to manufacture and supply approved products from the facility to the US market. We will work with the regulator to achieve fully compliant status,' the company said in a statement. Sun Pharmaceutical Industries is the world's leading specialty generics company with a presence in innovative medicines, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as global emerging markets. The company had reported 2.6% rise in consolidated net profit to Rs 3,118 crore on a 8.6% increase in revenue to Rs 14,405.2 crore in Q2 FY26 as compared with Q2 FY25. Powered by Capital Market - Live

Sun Pharmaceutical Industries announced that the US FDA conducted an inspection at the Company's Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). Powered by Capital Market - Live

Sun Pharmaceutical Industries announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis. 'ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to severe plaque psoriasis,' said Kirti Ganorkar, Managing Director, Sun Pharma. 'We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.' ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1744.2, up 0.7% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.28% on the day, quoting at 25949.3. The Sensex is at 84711.84, up 0.29%. Sun Pharmaceutical Industries Ltd has risen around 5.43% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 3.33% in last one month and is currently quoting at 22593.4, up 0.8% on the day. The volume in the stock stood at 8.35 lakh shares today, compared to the daily average of 17.57 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1748.4, up 0.53% on the day. Sun Pharmaceutical Industries Ltd is down 1.36% in last one year as compared to a 10.27% spurt in NIFTY and a 4.7% spurt in the Nifty Pharma index.The PE of the stock is 88.9 based on TTM earnings ending September 25.Powered by Capital Market - Live